Awatif Rashed Z. Almotairy^1,2, Eman Fayad³, Fatimah Hadadi⁴, Ahmad F. Alhomodi⁵, Dalal Nasser Binjawhar⁶, Hanadi A. Katouah⁷, Bassma H. Elwakil^8,*, Keshav Raj Paudel^9,10,*, Mostafa El-Khatib¹¹

Oncology Research, Vol.34, No.4, 2026, DOI:10.32604/or.2025.070645 - 23 March 2026

Abstract Objectives: Prostate cancer cells often develop mechanisms to evade conventional therapies. Nanomedicine offers the potential for targeted drug delivery, improved tumor accumulation, and reduced systemic toxicity. This study biosynthesizes silver nanoparticles (NPP/AgONPs) functionalized with propolis, evaluates their antibacterial efficacy against uropathogenic strains of Escherichia coli (E. coli), and assesses their cytotoxic effect on cancer cell proliferation using the PC-3, human prostate epithelial cell line. Methods: The synthesized NPP/AgONPs physiochemical parameters were characterized, followed by in vitro assays to evaluate their antibacterial activity against multiple uropathogenic E. coli strains; determining the cytotoxicity against HPrEC and PC-3 cells by measuring cytotoxicity (CC₅₀)… More >

HAIYANG CHEN^1,2,#, JINGYAO SU^1,#, DANYANG CHEN^1,#, YUYE DU¹, RUILIN ZHENG¹, QINGLIN DENG², QIANQIAN DU³, BING ZHU^1,*, YINGHUA LI^1,*

BIOCELL, Vol.46, No.10, pp. 2267-2273, 2022, DOI:10.32604/biocell.2022.020218 - 13 June 2022

Abstract At present, Hepatocarcinoma is one of the main causes of tumor related death all over the world. However, there are still many clinical restrictions on the treatment of liver cancer. Recently, L-Selenocystine has been shown to be a novel treatment for tumors, especially human glioma cells. But, the mechanism of L-Selenocystine against hepatocellular carcinoma remains unclear. Therefore, the main objective of this study was to investigate the effects of L-Selenocystine on HepG2 cell proliferation and activation of reactive oxygen species (ROS) mediated signaling pathway. L-Selenocystine can significantly inhibit HepG2 cell proliferation by activating caspase-3 and More >

Kazuo Umezawa^*, Andrzej Breborowicz^†, Shamil Gantsev^‡

Oncology Research, Vol.28, No.5, pp. 541-550, 2020, DOI:10.3727/096504020X15929100013698

Abstract There have been great advances in the therapy of cancer and leukemia. However, there are still many neoplastic diseases that are difficult to treat. For example, it is often difficult to find effective therapies for aggressive cancer and leukemia. An NF- B inhibitor named dehydroxymethylepoxyquinomicin (DHMEQ) was discovered in 2000. This compound was designed based on the structure of epoxyquinomicin isolated from a microorganism. It was shown to be a specific inhibitor that directly binds to and inactivates NF- B components. Until now, DHMEQ has been used by many scientists in the world to suppress… More >